The exchange protein directly activated by cAMP (Epac), which is primarily involved in cAMP signaling, has been known to be essential for controlling body energy metabolism. Epac has two isoforms: Epac1 and Epac2. The function of Epac1 on obesity was unveiled using Epac1 knockout (KO) mice. However, the role of Epac2 in obesity remains unclear. METHODS: To evaluate the role of Epac2 in obesity, we used Epac2a KO mice, which is dominantly expressed in neurons and endocrine tissues. Physiological factors related to obesity were analyzed: body weight, fat mass, food intake, plasma leptin and adiponectin levels, energy expenditure, glucose tolerance, and insulin and leptin resistance. To determine the mechanism of Epac2a, mice received exogenous leptin and then hypothalamic leptin signaling was analyzed. RESULTS: Epac2a KO mice appeared to have normal glucose tolerance and insulin sensitivity until 12 weeks of age, but an early onset increase of plasma leptin levels and decrease of plasma adiponectin levels compared with wild-type mice. Acute leptin injection revealed impaired hypothalamic leptin signaling in KO mice. Consistently, KO mice fed a high-fat diet (HFD) were significantly obese, presenting greater food intake and lower energy expenditure. HFD-fed KO mice were also characterized by greater impairment of hypothalamic leptin signaling and by weaker leptin-induced decrease in food consumption compared with HFD-fed wild-type mice. In wild-type mice, acute exogenous leptin injection or chronic HFD feeding tended to induce hypothalamic Epac2a expression. CONCLUSIONS: Considering that HFD is an inducer of hypothalamic leptin resistance and that Epac2a functions in pancreatic beta cells during demands of greater work load, hypothalamic Epac2a may have a role in facilitating leptin signaling, at least in response to higher metabolic demands. Thus, our data indicate that Epac2a is critical for preventing obesity and thus Epac2a activators may be used to manage obesity and obesity-mediated metabolic disorders. (2017) 41, 279-288; doi:10.1038/ijo.2016.208; published online 13 December 2016
INTRODUCTION
The prevalence of obesity increased dramatically in recent decades worldwide and is a substantial contributor to the epidemic of type 2 diabetes. [1] [2] [3] Body weight reduction improves a number of metabolic and cardiovascular risk factors. Despite the importance of weight control strategies in the prevention and management of obesity-related diseases, long-term results of lifestyle or drug interventions are generally disappointing. 4, 5 Therefore, better understanding of the molecular mechanisms underlying the development of obesity is crucial.
Body weight homeostasis is influenced by cyclic AMP (cAMP)-mediated signaling pathways, 6 which are involved in modulating insulin, 7 leptin 8, 9 and atrial natriuretic peptide (ANP) secretion. 10 In addition to cAMP-dependent protein kinase, exchange proteins directly activated by cAMP (Epac) 11 are also important targets of cAMP. Epac1 and Epac2 (Rapgef4) are the two isoforms. 12 Although Epac1 is ubiquitously present, splice variants of Epac2 are differentially expressed (Epac2a; brain/heart/beta-cell type, 2b; adrenal type, and 2c; liver type). 13, 14 Epac2a deletion caused impaired glucose-stimulated insulin secretion (GSIS) only when metabolic demand was high, 15 suggesting that Epac2a is important for ameliorating beta-cell function against obesity or insulin resistance. Epac2a in cardiomyocytes is involved in ANP secretion. ANP has an important role in blood pressure control and natriuretic action. 10 Moreover, evidence suggests that ANP participates in energy metabolism such as lipolysis 16, 17 and browning of adipose tissues. 18 However, the ANP effect associated with obesity is observed in humans, but not rodents.
It was recently reported that Epac1 knockout (KO) mice had exhibited reduced body weight and plasma leptin levels, and displayed increased leptin sensitivity, 19 demonstrating that hypothalamic Epac1 activation induces obesity by way of leptin resistance. Consistently, an adenylyl cyclase activator or Epac activator, but not a protein kinase activator, exacerbates leptin resistance in the hypothalamus. 20 Because the Epac activator used in this study 20 may be non-selective and as both Epac1 and Epac2a are expressed in the hypothalamus, Epac2a-selective function in leptin resistance should be further demonstrated.
In the present study, using Epac2a KO mice, we demonstrated the effect of Epac2a on leptin resistance and thus obesity.
MATERIALS AND METHODS

Animals and diets
Age-matched male C57BL/6 (wild-type, WT) mice were purchased from Jung-Ang Experimental Animals (Seoul, Korea). The Epac2a KO mice were generated as previously described. 7 Mice were initially fed a normal chow diet (10% of calories from fat, 70% from carbohydrates and 20% from proteins). From 4 weeks of age, the WT and Epac2a KO mice were fed a high-fat diet (HFD) for indicated weeks. The HFD was composed of 60% of calories from fat, 20% from carbohydrates and 20% from proteins (Research Diet Inc., New Brunswick, NJ, USA). Food intake and body weight were followed up every 4 days or everyday if necessary using an automatic BioDAQ system (Research Diet Inc.). The animals were housed under a daily 12 h light/12 h dark cycle. All animal experiments were approved by the Institutional Ethics Committee, Daegu, Korea (KM-2013-12).
Collection of blood and internal organ samples
At the end of the study, blood sample was collected from the orbital venous plexus. White (WAT) and brown adipose tissue (BAT), the liver, the pancreas and the hypothalamus were dissected out. Tissues were immediately frozen in liquid nitrogen and stored at − 80°C. Embedded tissue blocks were cut into 6-μm sections and stained with hematoxylin and eosin.
Plasma hormone and lipid measurements
Plasma leptin and adiponectin concentrations were determined using colorimetric sandwich enzyme-linked immunosorbent assay (ELISA) kits (Raybiotech Inc., Norcross, GA, USA and R&D systems, Minneapolis, MN, USA; respectively) following the manufacturer's instructions. Plasma total cholesterol, low-density lipoprotein, high-density lipoprotein, free fatty acid (FFA), and triglyceride were measured using an AU-480 analyzer (Beckman Coulter, Fullerton, CA, USA).
Intraperitoneal glucose tolerance test and insulin tolerance test
Intraperitoneal (i.p.) glucose tolerance (IPGTT) and insulin tolerance tests (ITT) were performed as previously described. 13 Briefly, WT and Epac2a KO mice were fasted for 12 h (IPGTT) or 4 h (ITT). For IPGTT, mice received an i.p. injection of glucose (1 g kg − 1 ). To observe insulin tolerance, an i.p. injection of human insulin (Eli Lilly, Indianapolis, IN, USA) at 0.5 mUg − 1 was performed. Tail blood samples were collected at 0, 15, 30, 60, 90 and 120 min. Blood glucose levels were measured using the Glucocard Test Strip II (Arkray Inc., Edina, MN, USA). Plasma insulin levels were measured by EIA using ultrasensitive insulin (Mercodia, Winston Salem, NC, USA).
Real-time PCR analysis
Tissue was homogenized in TRI reagent (Sigma-Aldrich, St Louis, MO, USA) using an Ultra-Turax T25 (IKA, Staufen, Germany). RNA was reverse transcribed to complimentary DNA from 1 μg of total RNA using a HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Quantitative real-time PCR was performed by Power SYBR Green PCR master mix using the Real-Time PCR 7500 system (Applied Biosystems). The expression level of glyceraldehyde 3-phosphate dehydrogenase (Gapdh) was used as an internal control. The reactions were incubated at 95°C for 10 min, followed by 45 cycles of 95°C for 15 s, 55°C for 20 s and 72°C for 35 s. PCR primers are listed in supplementary  Table S1 .
Ex vivo lipolytic activity
Adipose tissue from epididymis was harvested in age-matched WT and Epac2a KO mice fed a chow diet. About 20 mg of isolated fat tissue was placed in 30 mM HEPES buffer (1 ml, pH 7.4), which contains 120 nM NaCl, 4 mM KH 2 PO 4 , 1 mM MgSO 4 , 0.75 mM CaCl 2 , 10 mM NaHCO 3 . Lipolysis was amplified by isoproterenol (10 nM) for 4 h at 37°C. An NEFA-2HR kit (Wako Chemicals, Richmond, VA, USA) and glycerol determination kit (Sigma-Aldrich) were used to measure the concentrations of secreted FFA and glycerol, respectively. For measurement of protein content, the tissue was homogenized with lysis buffer, which contains 1% Triton X-100, 150 nM NaCl, 10 mM Tris-HCl (pH 7.5), 1 mM EDTA and 1% Nonidet P-40. Then, we used the Pierce BCA protein assay kit (Thermo Scientific, Waltham, MA, USA). pSTAT3 immunofluorescence staining Leptin (5 mg kg − 1 ; a recombinant murine type; PeproTech, Rocky Hill, NJ, USA) or 1 × phosphate-buffered saline (PBS) was i.p.-injected in male mice aged 7 weeks and fasted overnight. Intracardiac perfusion was achieved 45 min after leptin injection with PBS followed by 4% paraformaldehyde. The mouse brain was maintained in 4% paraformaldehyde at 4°C overnight and in a 30% sucrose solution for cryoprotection. Brains were embedded in Shandon Cryomatrix resin (Thermo Scientific) and kept at − 80°C. Brain was cut with 15 μm thickness and placed on glass slides. We performed pSTAT3 Y705 immunofluorescence staining according to a previous description. 19 The sections were consecutively exposed to 1% NaOH, 0.3% glycine and 0.03% sodium dodecyl sulfate (SDS) for 20, 20 and 10 min, respectively. They were then incubated for 1 h in 3% normal donkey serum-containing PBS with 0.4% Triton X-100 and 1% bovine serum albumin. Antibody for STAT3 phosphorylated at tyrosine 705 (rabbit anti-P-STAT3; 9131, Cell Signaling, Danvers, MA, USA) was added at a dilution of 1:1000 in blocking solution (PBS containing 0.4% Triton X-100, 1% bovine serum albumin and 3% goat serum) for overnight incubation at 4°C. The slides were washed three times for 5 min each with PBS − 0.4% Triton X-100 and then incubated with FITC-conjugated donkey anti-rabbit secondary antibody (711-095-152, Jackson ImmunoResearch, West Grove, PA, USA) at a dilution of 1:500 in blocking solution for 2 h at room temperature. The slides were then washed again with PBS containing 0.4% Triton X-100 three times for 5 min each and then mounted with anti-fade mounting medium with DAPI (4′,6-diamidino-2-phenylindole) (Invitrogen, Carlsbad, CA, USA). Images were acquired with a confocal microscope (Zeiss, Oberkochen, Germany).
Western blot analysis
Homogenates of mouse hypothalamic tissues were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting with anti-PTP1B (protein-tyrosine phosphatase 1B; ab52650, Abcam, Cambridge, MA, USA), SOCS-3 antibody (suppressor of cytokine signaling 3; ab16030, Abcam), anti-Epac2a (4156, Cell signaling), anti-pSTAT3 (9131, Cell signaling) and anti-GAPDH antibody (2118, Sigma-Aldrich). The immunoreactive bands were visualized using horseradish peroxidaseconjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and enhanced chemiluminescence (Amersham Biosciences, Little Chalfont, UK). The experiments were repeated at least three times.
Whole-body micro-CT scan and total volume measurement of the adipose tissue Mice images were obtained in a prone position on the CT couch. Anesthesia was achieved with 1-2% isoflurane carried by O 2 via a nostril cone tube. Siemens Inveon Multi-Modality micro-CT system (Siemens Preclinical Solutions, Malvern, PA, USA) was used for CT scans of mouse whole body. Exposure conditions of the high-resolution micro-CT were peak voltage of 70 kV, tube current of 0.5 mA and full rotations. The image reconstructions were carried out to achieve a voxel size of about 107 μm. Data analysis tool was Siemens Inveon research workplace software (Erlangen, Germany). The C1 to L6 vertebrae distance for body length was measured in mm. The total volume measurement of the adipose tissue was performed in three-dimensional (3D) volume punch mode on Siemens Syngo VE36a MultiModality workplace software (Erlangen, Germany). Coronal images reconstructed from 3D data were obtained with GE Advantage Workstation, version 4.0 (General Electric Medical Systems, Chicago, IL, USA).
Leptin sensitivity
For in vivo leptin sensitivity measurements, recombinant mouse leptin (2 mg kg − 1 ) or PBS was administered i.p. to HFD-fed male mice after an overnight fast. Leptin was i.p. injected every 12 h (morning and evening) for the indicated period of time (36 h). Body weight and food intake were monitored daily for 5 days. Body weight and baseline food intake measurements for the 2 days prior to the start of the experiment were averaged and used to calculate percent change.
Indirect calorimetry
Mice were placed by one and one in calorimetric chambers and spent for 10 days. The acclimation period was the first 5 days. Hence, data were recorded for the next 5 days. The indirect calorimetry system possessed a 16-chamber (TSE system, Chesterfield, MO, USA Administration of Sp-8-BnT-cAMPS (S220)
The selective Epac2 activator S220 (BIOLOG, Bremen, Germany) was tested on diet-induced obesity. Age-matched male mice were randomly allocated into three groups (five per each group): a normal chow diet, HFD and HFD plus S220. On 2-week HFD, mice i.p. received S220 (50 mg kg − 1 for 2 weeks and 20 mg kg − 1 for 2 weeks) or saline everyday (at 0900 hours) for 4 weeks. The chow group received 0.2 ml of saline. At the end of the experiment, mice were fasted overnight and anesthetized with isoflurane. Blood was collected from the inferior vena cava to determine the leptin concentration. Another experiment was performed to see the effect of S220 on hypothalamic leptin signaling; normal chow diet mice were randomly divided into four groups: vehicle, vehicle plus S220, leptin and leptin plus S220. Mice received S220 (20 mg kg − 1 , i.p.) or saline at 30 min prior to leptin (5 mg kg − 1 ) or PBS injection. Forty-five minutes after, mice were killed for further experiments.
Statistics
The results are expressed as mean ± s.e.m. SPSS version 14.0 (SPSS Inc., Chicago, IL, USA) was used. Comparisons between the two groups were performed using a Student's two-tailed t-test. For the comparison of more than two groups, the significance was tested using analysis of variance. Differences were considered significant if Po0.05. Sample size was chosen according to previous observations, which perform similar experiments to see significant results, or the results from our preliminary experiments. Variance was similar between the groups that are being statistically compared.
RESULTS
Epac2a KO mice presented more adiposity and higher plasma leptin levels To evaluate Epac2a function in obesity, we first compared the body weight and fat mass of Epac2a KO and WT mice fed with a chow diet. KO mice appeared generally healthy, with no obvious physiological abnormality. Body weights and food intake of WT and KO mice were similar until 12 weeks of age (Figures 1a and b) . However, the adipocyte size and fat storage in WAT were higher in KO mice than in WT mice (Figure 1c) . Adipose tissue secretes leptin and plasma leptin concentrations are positively associated with adipose tissue mass. [21] [22] [23] The average plasma leptin levels in WT mice were 5.97 ± 1.07 ngml (Figure 1d) . The average plasma adiponectin levels were lower in KO mice than in WT mice (Figure 1e) . Nevertheless, glucose tolerance, GSIS (Figure 1f ) and insulin sensitivity (Figure 1g) were not altered in KO mice. Epac2a has a central role in augmenting GSIS during periods of increased beta-cell secretory activity. However, it has a minor role in GSIS under basal conditions. 24 Consistent with this previous observation, KO mice exhibited no difference in insulin secretion under basal conditions (Figure 1f ).
The expression of lipolysis-related genes was decreased in KO mice To investigate the molecular mechanism of increased adiposity in Epac2a KO mice, lipogenic, adipogenic and lipolytic gene expression was examined. The expression of several adipogenic and lipogenic genes did not differ between WT and KO mice (Figure 2a) . In contrast, the expression of lipolytic genes was significantly downregulated in WAT from KO mice (Figure 2b) . These results suggest that increased adiposity is due to decreased lipolytic activity in KO mice. However, Epac2a was not expressed in WAT, but was expressed at high levels in the hypothalamus and heart (Figure 2c) . Thus, lipolysis downregulation in WAT was not due to loss of Epac2a in WAT itself. To confirm this, ex vivo lipolysis activity in epididymal WAT was studied using isoproterenol, a nonspecific β-adrenergic receptor agonist. There was no difference in FFA or glycerol release between the two groups under either basal or stimulated conditions (Figure 2d ). These results Figure 2 . Adipocytes in Epac2a KO mice lower lipolytic gene expression but lipolytic activity remains normal in response to beta-adrenergic stimulation. Relative expression of adipo-lipogenic genes (a) and lipolytic genes (b) in epididymal WAT from WT and KO mice on 12 weeks using real-time PCR (n = 9). (c) Distribution of Epac2a mRNA. RT-PCR analysis shows that Epac2a mRNA was expressed in the hypothalamus (Hypo) and heart, but not in skeletal muscle (SM), BAT, and WAT in WT mice. (d) Ex vivo lipolytic activity was measured on epididymal fat explants from WT or KO mice on chow diet (n = 6). FFA and glycerol release in response to isoproterenol (ISO) were measured in the incubation buffer. The values represent the mean ± s.e.m. *Po0.05 vs WT mice, suggest that adipocytes from KO mice present a normal lipolytic sensitivity. Thus, decreased expression levels of lipolytic genes in WAT suggest decreased extracellular lipolytic stimuli.
Epac2a ablation suppresses leptin signaling Epac activity is involved in leptin signaling in the hypothalamus 19, 20 and Epac2a is important in beta cells for higher insulin secretion in response to sulfonylureas, incretins and diet-induced obesity. 15 To determine whether the consequence of Epac2a loss is associated with leptin resistance, we compared STAT3 phosphorylation (pSTAT3) in the hypothalamus of WT and KO mice. Immunofluorescence staining indicated that pSTAT3 (Y705) was shown in the nucleus of the arcuate nucleus and ventromedial hypothalamus (Figure 3a ), well matched with previously observed data. 20 WT mice displayed more prominent nuclear immunostaining of pSTAT3 of arcuate nucleus and ventromedial hypothalamus in response to leptin than KO mice (Figure 3b and Supplementary Figure S1 ). This was also true for the pSTAT3 protein levels (Figures 3c and d) . In addition, Epac2a Epac2a KO mice are susceptible to developing obesity To amplify the impact of Epac2a ablation associated with obesity and leptin resistance, mice were fed a HFD for 8 weeks. KO mice significantly gained more weight than WT mice (Figure 4a) . At the end of the HFD feeding, the greater body fat mass was also observed in KO mice (Figures 4b and c) , without an alteration in body length (Figure 4d ). Histological examination of the epididymal WAT, BAT and liver revealed that KO mice accumulated more lipids than WT mice (Figures 4d and e) . Fasting plasma cholesterol and triglyceride levels tended to increase, but plasma FFA levels were lower in KO mice (Supplementary Table S2 ). In addition, KO mice had worse glucose intolerance (Figure 4f ) and insulin resistance (Supplementary Figure S2a) . Fasting blood glucose and plasma insulin levels were elevated in HFD-fed KO mice (Supplementary Figure S2b) . The pancreas morphometric analyses of WT mice on a HFD revealed an increase in pancreas weight (data not shown) and islet size (Supplementary Figure S2c) compared with their littermates on normal diet. KO mice on a HFD exhibited larger pancreas weight and islet size than WT mice on a HFD, but the differences were not significant.
Leptin resistance in HFD-fed Epac2a KO mice We examined the average daily and cumulative food intake during 8 weeks of HFD feeding. Food intake was higher in KO mice after 5 weeks of HFD feeding (Figure 5a ). From that point onward, the daily food intake of WT mice somewhat decreased, whereas that of KO mice increased. Thus, cumulative food intake was substantially higher in KO mice than that of WT mice (Figure 5b) . Consistent with the results in normal chow diet, Epac2a KO mice had higher plasma leptin and reduced adiponectin levels than WT mice (Figure 5c) . We then performed an in vivo leptin resistance test. We determined that KO mice were resistant to the effects of leptin (2 mg kg − 1 per injection, i.p.), whereas WT mice were not (Figure 5d ). Consistent with this in vivo study, the basal levels of SOCS-3 and PTP1B, important markers of leptin resistance, [25] [26] [27] were higher in the hypothalamus of KO mice (Figure 5e ). Leptin has an important role in the maintenance of energy balance by reducing food intake, 28 mainly by proopiomelanocortin (POMC) secretion from the hypothalamic arcuate nucleus. KO mice fed a HFD presented decreased Pomc mRNA expression levels (Figure 5f ), although there was no significant change in the hypothalamic neuropeptide Y (Npy) mRNA expression. To reiterate the fact that HFD-fed KO mice are vulnerable to leptin resistance, we tested whether HFD is related with hypothalamic Epac2a expression (Figure 5g ). Remarkably, 8-week-HFD feeding tended (c) Coronal projection images of 3D reconstructions of micro-CT scans of WT and KO mice after 8 weeks of HFD feeding. The fat/total body ratio was determined by whole-body CT imaging (n = 6). (d) Body length and various tissue weights in absolute amounts from WT and KO mice after 8 weeks of HFD feeding (n = 9). (e) Representative images of H&E-stained sections of Epi (×100), BAT (×200) and liver (×200) from WT and KO mice after 8 weeks of HFD feeding. Tissue blocks were cut into 6-μm sections and stained with H&E. Scale bar, 100 μm. (f) Intraperitoneal glucose tolerance test (blood glucose and plasma insulin levels) in WT and KO mice after 8 weeks of HFD feeding (n = 9). The values represent the mean ± s.e.m. *P o0.05, **P o0.01 vs WT mice.
to increase Epac2a expression in the hypothalamus of WT mice compared with normal chow diet, although data were not statistically significant, possibly due to the limited sample size and/or duration of HFD feeding. In addition, energy expenditure, another marker of leptin resistance, in KO mice fed a HFD was lower than that of WT mice (Supplementary Figures S3 and S4) , although resting locomotor activity did not differ between WT and Epac2a KO mice.
Effect of S220 on HFD-induced increase in body weight and plasma leptin levels To elucidate whether Epac2 activation ameliorates HFD-induced obesity, we employed the selective Epac2 activator S220. 29 When S220 was acutely treated in WT mice fed a chow diet, hypothalamic pSTAT3 expression showed an increasing trend, when compared with PBS-treated control (Figure 6a ). By only a 4-week administration with S220 on a HFD, body weight gain was dramatically alleviated (Figure 6c ), whereas food intake did not differ from the PBS-treated HFD group (Figure 6b) . Furthermore, plasma leptin levels on a HFD were significantly ameliorated by the treatment with S220 for 4 weeks, when compared with HFD group treated with PBS ( Figure 6d ).
DISCUSSION
Over the last few years, several studies involving Epac1, Epac2a or Epac1/2 double KO mice have been published. 13, 15, 19, [30] [31] [32] Experiments using Epac1 KO mice revealed diverse functions of Epac1 associated with cancer metastasis, 31 beta-cell dysfunction 32 and leptin resistance. 19 In addition, studies indicated that Epac1 is involved in the inhibition of IL6 response, 33 attenuation of chronic kidney disease, 34 age-related skeletal muscle derangement, 35 promotion of adipocyte differentiation 36 and ghrelin signaling. 37 Diverse actions of Epac1 may be due to its wide tissue distribution. In contrast, only few studies report functions of Epac2a, which is expressed in few tissues, including the brain and neuroendocrine and endocrine tissues. In this study, Epac2a function was investigated in relation to obesity. Epac2a KO mice on normal chow diet exhibit elevated leptin and lowered adiponectin plasma levels, but normal glucose and lipid metabolism at least until 12 weeks of age. However, acute high dose of leptin injection or chronic metabolic stimulation such as a HFD reveals abnormal leptin signaling within the hypothalamus. In addition, we confirmed Epac2a expression in the hypothalamus and heart, but not in WAT, BAT and skeletal muscle. These results indicate that the premature elevation of plasma leptin levels in KO mice does not stem from adipocytes. In cardiomyocytes, Epac2a induces ANP secretion through GLP-1 receptor activation. 10 In humans, increased ANP levels due to genetic polymorphisms are associated with a lower prevalence of obesity and metabolic disorder. 38, 39 This association is mainly due to the stimulatory role of ANP in lipolysis, which is demonstrated in primate, but not in rodents. [39] [40] [41] Therefore, even if there is a defect in ANP secretion in Epac2a KO mice, it cannot be a primary cause of abnormally increased plasma leptin levels. In beta cells, Epac2a enhances insulin secretion by incretins, pharmacological drugs and a high-calorie diet. 13, 15, 42 Impaired function of beta cells, which also express Epac2a, may be a candidate, because beta-cell Epac2a has an important role in insulin secretion. However, it is only involved during high insulin demand 15 and Epac2a KO mice did not exhibit significant decrease in GSIS when plasma leptin levels were already elevated. Nevertheless, it could accelerate the leptin resistance development in HFD-fed Epac2a KO mice, which showed significant glucose intolerance and insulin resistance. This may be because appropriate insulin signaling in the hypothalamus is critical for leptin sensitivity through enhancement of phosphoinositide 3-kinase activity, thus increasing Pomc and decreasing Npy expression. 43, 44 Amelioration of leptin sensitivity by Epac1 ablation is well demonstrated and KO mice presented reduced WAT, reduced plasma leptin levels and resistance to diet-induced obesity, which contrasts the present results. They also demonstrated that, with a normal chow diet, body weight and adiposity were reduced in Epac1 KO mice, in contrast to Epac2a KO mice, which exhibited a significant gain in body weight and adiposity, and reduced energy expenditure only when fed a HFD. The results from Fukuda et al. 20 also indicates that cAMP signaling within the hypothalamus preferentially exploits Epac1, demonstrating that elevation of cAMP levels or an Epac activator impairs multiple signaling cascades activated by leptin, which is independent of the protein kinase pathway. Therefore, in the hypothalamus, Epac1 and Epac2a may have opposite roles with non-equal potencies (Epac144Epac2a) in response to certain identical signaling associated with leptin function such as cAMP. Alternatively, upstream regulators for the differential regulation of Epac1 and Epac2a may exist in the hypothalamus besides cAMP signaling. For example, sulfonylureas, which primarily target ATP-sensitive potassium channels, can activate Epac2a directly by allosteric binding, but not through cAMP signaling, in beta cells to augment insulin secretion. 45 In addition, various plasmalemmal receptors, including growth factor and cytokine receptors, activate Epac2 differentially from Epac1 independently of cAMP. 46 Therefore, novel modulators of hypothalamic Epac2a may be identified in the future to develop drugs against leptin resistance.
Consistent with our hypothesis that Epac1 preferentially participates in leptin signaling within the hypothalamus rather than Epac2a, at least in the basal conditions, Epac1 ablation in beta cells showed severer impairment in GSIS with deranged islet architecture, 32 in contrast to Epac2a-ablated beta cells showing defects in GSIS only when insulin secretory demand is high. 15 Therefore, the hypothalamus may share Epac2a function with beta cells, mainly playing a role in urgent conditions like high calorie intake or hyperleptinemia.
In conclusion, we demonstrate hypothalamic Epac2a that is utilized to augment leptin signaling and differentially regulated from Epac1. Besides hypothalamic selective Epac1 inhibition, we suggest that Epac2a activation is also helpful to manage leptin resistance in obesity and related metabolic disorders. In addition to its hypothalamic effect, Epac2a will also positively act on beta cells and cardiomyocytes to normalize body energy metabolism in humans.
